Back to Search
Start Over
Image-based ex vivo drug screen to assess targeted therapies in recurrent thymoma
- Source :
- Lung Cancer. 145:27-32
- Publication Year :
- 2020
- Publisher :
- Elsevier BV, 2020.
-
Abstract
- Objectives Thymoma is a rare malignancy derived from the thymic epithelial cells. No standard salvage treatments are available for recurrent thymoma and due to the low number of cases, alternative treatment regimens have been assessed only in small case series with varying success. The aim of this study was to use an image-based ex vivo drug screening strategy to assess efficacy of a large panel of anti-cancer agents for thymoma using patient derived tumor cells. Materials and Methods Vital tumor and tumor associated cells were used to assess the efficacy of 147 anti-cancer drugs including approved and experimental agents. Drug efficacy was analyzed at single cell resolution using image-based high content drug screening to assess tumor cell specific responses. Molecular profiling and histopathology was used to confirm the drug targets identified by the screen. Results The ex vivo drug screen identified selective sensitivity of the cancerous epithelial thymoma cells to EGFR-, HDAC- and mTOR-inhibition. Histopathology confirmed high protein level expression of EGFR in the patient’s tumor. Patient was initiated treatment with Cetuximab resulting in stable disease after relapse on five different chemotherapy regimens. Conclusion The results show that the image-based ex vivo therapy efficacy screening strategy can be used to identify patient and tumor relevant drug sensitivity patterns in thymoma. The results also warrant continued research on EGFR as a biomarker and therapy target in recurrent thymomas.
- Subjects :
- 0301 basic medicine
Pulmonary and Respiratory Medicine
Oncology
Cancer Research
medicine.medical_specialty
Lung Neoplasms
Thymoma
medicine.medical_treatment
Malignancy
Targeted therapy
Efficacy
03 medical and health sciences
0302 clinical medicine
Internal medicine
Humans
Medicine
Chemotherapy
Cetuximab
business.industry
Thymus Neoplasms
medicine.disease
030104 developmental biology
Pharmaceutical Preparations
030220 oncology & carcinogenesis
Personalized medicine
Neoplasm Recurrence, Local
business
Ex vivo
medicine.drug
Subjects
Details
- ISSN :
- 01695002
- Volume :
- 145
- Database :
- OpenAIRE
- Journal :
- Lung Cancer
- Accession number :
- edsair.doi.dedup.....b32229326bfdf6d5d9c128dba6c54c55